Author: tmgadmin
DATA FROM PHASE 1 TRIAL OF TRIPLEX VACCINE FOR CONTROL OF CYTOMEGALOVIRUS PUBLISHED IN BLOOD
HELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES
FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS